DiaMedica's DM199 (Rinvecalinase Alfa) Advances in Preeclampsia and Stroke: Phase 2 Data, Regulatory Milestones, and Market Outlook
Key Insights
Rinvecalinase alfa (DM199), a recombinant human tissue kallikrein-1 (search) protein, is being developed by DiaMedica Therapeutics (search) for preeclampsia (search) and acute ischemic stroke (search), with the preeclampsia therapeutics market projected to reach USD 3,214.3 million by 2036 at a 10.0% CAGR.
Interim Phase 2 results reported in July 2025 showed dose-dependent blood pressure reductions and no placental transfer among 28 preeclampsia (search) participants, supporting the drug's disease-modifying potential targeting endothelial dysfunction.
DiaMedica received Health Canada clearance in March 2026 for a Phase 2 early-onset preeclampsia (search) study and dosed the first patients in a Phase 2 fetal growth restriction (search) trial in June 2026, while the ReMEDy2 Phase 2/3 stroke trial reached 75% enrollment in May 2026.
DiaMedica Therapeutics (search) is advancing its investigational biologic DM199 (rinvecalinase alfa) across two high-unmet-need indications—preeclampsia (search) and acute ischemic stroke (search)—with a series of clinical and regulatory milestones reshaping the development timeline in 2025 and 2026. The recombinant human tissue kallikrein-1 (search) protein is designed to address endothelial dysfunction, a mechanism that distinguishes it from conventional symptom-management approaches in both disease areas. According to market analysis from Future Market Insights, the rinvecalinase alfa preeclampsia therapeutics market is projected to grow from USD 1,239.3 million in 2026 to USD 3,214.3 million by 2036, reflecting a 10.0% compound annual growth rate.
Interim Phase 2 Results Signal Disease-Modifying Potential
In July 2025, DiaMedica Therapeutics (search) reported positive interim Phase 2 results for DM199 in preeclampsia (search). The data, drawn from 28 participants, demonstrated dose-dependent reductions in blood pressure and, critically, no placental transfer of the biologic. These findings support the therapeutic hypothesis that rinvecalinase alfa can improve maternal hemodynamics without clinically meaningful fetal exposure—a central concern in pregnancy drug development. The company noted that the Phase 2 Part 1a study achieved its prespecified dose-escalation objectives.
The World Health Organization reported in July 2025 that an estimated 10 million women develop preeclampsia (search) each year, and in December 2025 stated that the condition affects 3% to 8% of women who give birth worldwide. WHO also noted that magnesium sulfate can reduce eclampsia risk by more than half among women with preeclampsia, underscoring both the disease burden and the limitations of current therapies, which manage symptoms rather than modifying the underlying disease process.
Regulatory Progress and Hurdles Across Jurisdictions
DiaMedica's regulatory trajectory has been marked by both advances and additional requirements. In March 2026, Health Canada issued a No Objection Letter for a Phase 2 study of DM199 in early-onset preeclampsia (search), enabling trial initiation in Canada and supporting a planned multicountry program across North America and the United Kingdom. This authorization shifted rinvecalinase alfa from investigator-sponsored evidence toward sponsor-controlled dose selection.
However, in June 2026, DiaMedica received written FDA feedback concerning additional nonclinical reproductive-toxicity data for its preeclampsia (search) development program. The agency requested exposure and activity evidence from a completed rat study and prompted a new pharmacokinetic study. The company planned a rat pharmacokinetic and activity study to address exposure and pharmacologic-effect questions. This requirement echoes an earlier FDA request from December 2025, when meeting minutes called for an additional modified embryo-fetal development and pre-postnatal development study.
In the United Kingdom, the Health Research Authority recorded a favorable ethics opinion on August 28, 2025 for the ReMEDy2 trial, specifying intravenous plus subcutaneous dosing with repeated biological sampling. The UK market for rinvecalinase alfa pharmacokinetic studies is projected to grow at 7.6% CAGR through 2036, supported by coordinated regulatory and ethical review pathways.
Clinical Program Expansion: Fetal Growth Restriction (search) and Stroke
DiaMedica expanded its pregnancy-related development program in June 2026, announcing the dosing of the first two patients in a Phase 2 fetal growth restriction (search) trial of DM199. The study evaluates three dose levels in up to thirty participants and includes cord-blood exposure assessment, extending pharmacokinetic work into a distinct pregnancy population with specialized maternal and fetal sampling requirements.
On the stroke front, the ReMEDy2 Phase 2/3 acute ischemic stroke (search) trial reached a significant enrollment milestone in May 2026, with DiaMedica reporting that enrollment had reached 75% of the two-hundred-patient threshold for its planned interim analysis. The milestone reflected approximately seventy activated sites across the United States and several international markets. ClinicalTrials.gov listed ReMEDy2 as recruiting on April 28, 2026, with sixty-six locations and numerous United States hospitals.
Competitive Landscape in Preeclampsia (search) Therapeutics
DiaMedica is not alone in pursuing disease-modifying therapies for preeclampsia (search). Comanche Biopharma (search) is advancing CBP-4888, a placenta-targeted siRNA candidate designed for sFlt1-mediated preterm preeclampsia. In April 2025, the European Medicines Agency granted orphan drug designation to CBP-4888, and in January 2025, the UK Innovative Licensing and Access Pathway Steering Group awarded an Innovation Passport to the candidate. Comanche states that no approved therapy modifies preeclampsia progression and that CBP-4888 remains investigational, with the company currently excluding expanded-access requests.
The acute-care segment includes established players: Pfizer and Baxter provide magnesium sulfate products, Hikma Pharmaceuticals supplies labetalol injection, and Fresenius Kabi supports seizure-prevention protocols with magnesium sulfate. Catalent serves as the contract manufacturer for DM199 drug substance, operating under Novo Holdings ownership following the completed acquisition announced in February 2025.
Market Structure and Service Ecosystem
The pharmacokinetic studies market supporting rinvecalinase alfa development is projected to reach USD 1,750.0 million by 2036, growing at a 7.1% CAGR from USD 881.3 million in 2026. Phase I studies are projected to hold 45.7% of the study phase category in 2026, while preeclampsia (search) represents an estimated 43.2% of the indication category. Single ascending dose studies are forecast to account for 44.9% of the study type category, and pharma companies are expected to hold 66.4% of the sponsor share.
Integrated clinical research organizations—including IQVIA, ICON plc, Thermo Fisher Scientific PPD, and Fortrea—provide multinational trial operations and pharmacokinetic analysis capabilities. ICON expanded its U.S. early-phase footprint in May 2026 with a 69,500-square-foot clinical research unit in San Antonio. BioAgilytix announced multi-million-dollar LC/MS investments in October 2025, expanding laboratory capacity in Germany and the United States for complex biologic assays.
Analyst Perspective on Development Strategy
Anurag Sharma, Principal Analyst at Future Market Insights, emphasized that executive decisions should separate current symptom management from investigational therapies whose regulatory and reproductive-safety evidence remains incomplete. "Clinical teams should define eligible patients and measurable maternal-fetal outcomes before adding treatment complexity to high-risk pregnancy pathways," Sharma noted. The analyst further advised that "developers should align manufacturing scale with realistic enrollment and authorization timelines rather than projected market values."
The country-level outlook reveals Japan forecast at 12.5% CAGR for preeclampsia (search) therapeutics, Germany at 10.2%, the UK at 9.3%, the USA at 7.9%, and South Korea at 7.6%. For pharmacokinetic studies, the UK leads at 7.6% CAGR, followed by South Korea at 7.3%, the USA at 6.7%, Japan at 5.8%, and Germany at 5.4%. These varying growth rates reflect differences in regulatory pathways, specialist-center capacity, and clinical trial infrastructure rather than current market size alone.